The Role of Care Coordination in Prostate Cancer Screening

Prostate cancer is the most commonly diagnosed cancer among men in the United States, accounting for nearly 30% of all new male cancer cases, according to the American Cancer Society. Yet it can be difficult to catch early because it often develops without noticeable symptoms. A patient may feel completely fine, while still being overdue for a screening or follow-up discussion that could be critical to early detection.

The work to screen for prostate cancer does not end when a provider raises the issue in the exam room. In many cases, the real challenge begins after the visit, when patients are most likely to fall off track, and when recommended next steps can start to fade in their memory.

This often overlooked yet critical stage is where CareHarmony focuses its support; helping providers stay connected with patients and ensuring important follow-up does not stall or fall through the cracks.

Who may be at higher risk

Not every patient faces the same level of risk of developing prostate cancer. Age is one of the clearest factors, with risk generally increasing after the age of 50. Family history can also increase risk.

Black men in particular face a heavier burden, with higher rates of diagnosis and a greater likelihood of dying from the disease. They are about twice as likely to die from prostate cancer as White men, according to the American Cancer Society, and are often diagnosed at younger ages.

These risk factors matter, because delays do not affect every patient the same way. When a patient is already at elevated risk, a missed screening or slow follow-up is not a small gap in the process. It can change whether cancer is caught early, when the path forward is often more manageable and treatment decisions may be less complex.

It also means the next step should not feel generic. Some patients may be ready to act right away. Others may need more explanation, reassurance, or more support to stay on track. In prostate cancer especially, where screening decisions can feel uncertain or nuanced, patients may hesitate without additional guidance. Risk may shape the clinical picture, but it also shapes how much follow-through matters and how carefully that process needs to be supported.

Screening is important, but it is only the beginning

For patients who are at greater risk, screening is an important first step. A PSA blood test is often one of the first tools used to flag whether more attention may be needed, but screening is rarely a one-and-done event. It can lead to lab work, review of results, repeat testing, or additional evaluation depending on what comes back and what the patient’s broader risk picture looks like.

Screening rates, however, remain inconsistent, with only about 38% of men ages 55–69 reporting a PSA test within the past year, according to the National Cancer Institute.

This is where the process often becomes more fragile than it appears on paper. A provider may recommend testing and the patient may agree before leaving the visit. But that still does not guarantee follow-through. Once the visit is over, it becomes much easier for the next step to get delayed, pushed aside, or simply lose momentum.

For prostate cancer in particular, follow-up can be especially inconsistent. Patients may feel unsure about the necessity of testing, unclear on next steps, or less urgency due to a lack of symptoms, making it easier for screening to stall after the initial conversation.

In other words, the screening conversation may go exactly as planned, while the process that follows begins to break down after the visit. It’s an important distinction, especially in preventive care, where a patient may not feel any symptoms and may not immediately understand why timing matters.

Where care often breaks down

Most providers already know this pattern well. The challenge is typically not figuring out who needs follow-up; it’s finding the time and capacity to keep follow-ups moving forward.

After an appointment, staff are pulled in a dozen directions at once: referrals, authorizations, scheduling, patient calls, inbox messages, and everything else that keeps a practice running. In that environment, preventive follow-up can be harder to sustain, especially when the patient is not feeling symptoms and the next step does not seem urgent at the moment.

This is often where prostate cancer screening starts to break down. The plan may be clear during the visit, but can quickly lose priority once the patient returns to daily life and the practice shifts to competing demands.

A better way to keep patients from falling through the cracks

The challenge is not simply identifying which patients may need screening or follow-up. It is creating enough continuity after the visit for those next steps to actually happen.

This is where CareHarmony’s approach can make a real difference. By helping providers stay connected with patients between visits, CareHarmony gives practices a more consistent way to keep follow-up from losing stalling over time. And through CareBlocks, structured, patient-specific outreach can be tailored based on individual risk, readiness, and needs rather than delivered as one-size-fits-all communication.

In the context of prostate cancer screening, this may mean reinforcing why a PSA test was recommended, following up when lab work has not been completed, or helping uncover an issue that may not have come up during the visit itself. The goal is not more outreach; it is more relevant, timely engagement that helps patients move forward with confidence.

Turning screening into follow-through

Screening matters, but it is only valuable if patients are able to move through what comes next. Follow-up planning deserves more attention in conversations about prostate cancer. Better coordination can meaningfully change the shape of care by making the period after the visit more structured and easy to follow.

This is especially important as prostate cancer incidence has begun to rise again in recent years—particularly for more advanced-stage diagnoses—according to the American Cancer Society.

When patients have support between visits, there is less room for delays, confusion, or silence to derail the process. And when that support is more personalized, it becomes easier to meet patients where they are instead of assuming every next step will unfold the same way.

Early detection can make a meaningful difference in prostate cancer. But getting there depends on more than raising awareness. It also depends on helping patients stay connected long enough to take the next step, complete what has been recommended, and remain engaged if further evaluation is needed.

CareHarmony helps health systems close these gaps by delivering consistent, coordinated support between visits, turning screening into meaningful follow-through and helping patients navigate next steps with greater clarity and confidence.

Learn more about how your organization can strengthen care coordination and improve patient engagement.